The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Isatuximab and pomalidomide for the treatment of MM
Joseph Mikhael, MD, from the Mayo Clinic, Phoenix, AZ, USA, provides us with an insight into the high efficacy of isatuximab, an anti-CD38 monoclonal antibody, in treating patients with heavily relapsed multiple myeloma (MM), who are eligible for treatment with pomalidomide, as tested in a Phase I trial. He also describes challenge associated with this form of therapy, namely the significantly increased degree of leukopenia in patients undergoing a combination of isatuximab and pomalidomide and concludes with a note on how it is possible to control these side effects. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
